Furui Co.,Ltd(SZ:300049)2023-05-12 07:18Group 1: Financial Performance - The company received a total of 280 million CNY in special government funding, which was distributed in batches over previous years [1] - In 2022, Echosens achieved a revenue of 86.42 million EUR, representing a growth of 21.75% compared to the previous year [2] - As of May 10, 2023, the number of shareholders reached 13,855 [3] Group 2: Product Development and Market Strategy - The company is focusing on the NASH (Non-Alcoholic Steatohepatitis) field, with ongoing clinical trials for multiple NASH drugs [2] - FibroScan, a key product, had over 90% of its sales revenue generated from overseas markets in 2022 [2] - The company launched FibroScan GO in 2022, targeting primary healthcare institutions with a per-use charging model, which is currently being piloted in the US and France [2] Group 3: Research and Development - The company is actively collaborating with major international pharmaceutical companies to support drug clinical trials and provide comprehensive solutions [2] - The current focus in NASH drug development includes companies like Intercept, Madrigal, Pfizer, and others that have reached clinical endpoints [3] - The company is in the early trial phase for its Cordyceps project and cannot yet provide profit contributions [3]